trending Market Intelligence /marketintelligence/en/news-insights/trending/4JH_ohD3YsJKKzPmNsCrYg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Strongbridge Biopharma closes share offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Strongbridge Biopharma closes share offering

Strongbridge Biopharma plc closed its underwritten public offering of 4 million shares for net proceeds of about $23.4 million.

The company plans to use net proceeds to advance its drug pipeline, including Keveyis to treat primary periodic paralysis and Recorlev to treat Cushing's syndrome, and for other general corporate purposes and general and administrative expenses.

Cantor Fitzgerald & Co. acted as the sole book-running manager and Oppenheimer & Co. Inc. and H.C. Wainwright & Co. LLC acted as co-managers for the offering.